Effects of biologics on psychological status and quality of life in patients with inflammatory bowel disease : a multicenter study
Objective: To investigate the effects of biologics on psychological status and quality of life in patients with inflammatory bowel disease (IBD). Methods: A cross-sectional survey was conducted in 42 hospitals in 22 provinces (autonomous regions and municipalities directly under the central government) from September 2021 to May 2022. General clinical information and the use of biologics were obtained from adult patients diagnosed with IBD who voluntarily participated in the study. Psychological status was evaluated using the Generalized Anxiety Disorder (GAD-7), Patient Health Questionnaire-9 (PHQ-9), Pittsburgh Sleep Quality Index (PSQI), and Inflammatory Bowel Disease Questionnaire (IBDQ) assessment tools. Counts were analyzed via the Chi-square test, and datasets that were not normally distributed were analyzed via nonparametric tests. P<0.05 was considered statistically significant. Results: A total of 2 478 valid questionnaires were collected. The GAD-7 score of the biologics group was significantly lower than that of the non-use group [6 (2, 9) vs. 7 (3, 10), Z=-3.49, P<0.001]. IBDQ scores [183 (158, 204) vs. 178 (152, 198), Z=-4.11, P<0.001], intestinal symptom scores [61 (52, 67) vs. 58 (49, 65), Z=-5.41, P<0.001], systemic symptom scores [28 (24, 32) vs. 27 (23, 31), Z=-2.37, P=0.018], emotional ability scores [69 (58, 77) vs. 67 (56, 75), Z=-3.58, P<0.001] and social ability scores [26 (22, 29) vs. 25 (22, 29), Z=-2.52, P=0.012] in the biologics group were significantly higher than in the non-use group. GAD-7 scores [5 (2, 9) vs. 6 (3, 10), Z=-3.50, P<0.001] and PSQI scores [6 (4, 9) vs. 6 (4, 9), Z=-2.55, P=0.011] were significantly lower in the group using infliximab than in the group not using it. IBDQ scores were significantly higher in patients using vedolizumab than in those not using it [186 (159, 205) vs. 181 (155, 201), Z=-2.32, P=0.021] and were also significantly higher in the group treated with adalimumab than in the group not treated with adalimumab [187 (159, 209) vs. 181 (155, 201), Z=-2.16, P=0.030]. However, ustekinumab had no significant effect on any of the scores. Conclusion: The use of biologics is strongly associated with improvements in anxiety status and quality of life in IBD patients.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
---|---|
Enthalten in: |
Zhonghua nei ke za zhi - 62(2023), 8 vom: 01. Aug., Seite 1000-1006 |
Sprache: |
Chinesisch |
---|
Beteiligte Personen: |
Wei, S C [VerfasserIn] |
---|
Links: |
---|
Themen: |
Adalimumab |
---|
Anmerkungen: |
Date Completed 03.08.2023 Date Revised 03.08.2023 published: Print Citation Status MEDLINE |
---|
doi: |
10.3760/cma.j.cn112138-20220818-00603 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM360278159 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM360278159 | ||
003 | DE-627 | ||
005 | 20231226082655.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||chi c | ||
024 | 7 | |a 10.3760/cma.j.cn112138-20220818-00603 |2 doi | |
028 | 5 | 2 | |a pubmed24n1200.xml |
035 | |a (DE-627)NLM360278159 | ||
035 | |a (NLM)37528039 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a chi | ||
100 | 1 | |a Wei, S C |e verfasserin |4 aut | |
245 | 1 | 0 | |a Effects of biologics on psychological status and quality of life in patients with inflammatory bowel disease |b a multicenter study |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 03.08.2023 | ||
500 | |a Date Revised 03.08.2023 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Objective: To investigate the effects of biologics on psychological status and quality of life in patients with inflammatory bowel disease (IBD). Methods: A cross-sectional survey was conducted in 42 hospitals in 22 provinces (autonomous regions and municipalities directly under the central government) from September 2021 to May 2022. General clinical information and the use of biologics were obtained from adult patients diagnosed with IBD who voluntarily participated in the study. Psychological status was evaluated using the Generalized Anxiety Disorder (GAD-7), Patient Health Questionnaire-9 (PHQ-9), Pittsburgh Sleep Quality Index (PSQI), and Inflammatory Bowel Disease Questionnaire (IBDQ) assessment tools. Counts were analyzed via the Chi-square test, and datasets that were not normally distributed were analyzed via nonparametric tests. P<0.05 was considered statistically significant. Results: A total of 2 478 valid questionnaires were collected. The GAD-7 score of the biologics group was significantly lower than that of the non-use group [6 (2, 9) vs. 7 (3, 10), Z=-3.49, P<0.001]. IBDQ scores [183 (158, 204) vs. 178 (152, 198), Z=-4.11, P<0.001], intestinal symptom scores [61 (52, 67) vs. 58 (49, 65), Z=-5.41, P<0.001], systemic symptom scores [28 (24, 32) vs. 27 (23, 31), Z=-2.37, P=0.018], emotional ability scores [69 (58, 77) vs. 67 (56, 75), Z=-3.58, P<0.001] and social ability scores [26 (22, 29) vs. 25 (22, 29), Z=-2.52, P=0.012] in the biologics group were significantly higher than in the non-use group. GAD-7 scores [5 (2, 9) vs. 6 (3, 10), Z=-3.50, P<0.001] and PSQI scores [6 (4, 9) vs. 6 (4, 9), Z=-2.55, P=0.011] were significantly lower in the group using infliximab than in the group not using it. IBDQ scores were significantly higher in patients using vedolizumab than in those not using it [186 (159, 205) vs. 181 (155, 201), Z=-2.32, P=0.021] and were also significantly higher in the group treated with adalimumab than in the group not treated with adalimumab [187 (159, 209) vs. 181 (155, 201), Z=-2.16, P=0.030]. However, ustekinumab had no significant effect on any of the scores. Conclusion: The use of biologics is strongly associated with improvements in anxiety status and quality of life in IBD patients | ||
650 | 4 | |a Multicenter Study | |
650 | 4 | |a English Abstract | |
650 | 4 | |a Journal Article | |
650 | 7 | |a Adalimumab |2 NLM | |
650 | 7 | |a FYS6T7F842 |2 NLM | |
650 | 7 | |a Biological Products |2 NLM | |
700 | 1 | |a Liu, C |e verfasserin |4 aut | |
700 | 1 | |a Chen, M |e verfasserin |4 aut | |
700 | 1 | |a Cai, Y H |e verfasserin |4 aut | |
700 | 1 | |a Wu, X H |e verfasserin |4 aut | |
700 | 1 | |a Chen, M L |e verfasserin |4 aut | |
700 | 1 | |a Zhang, J X |e verfasserin |4 aut | |
700 | 1 | |a Xiang, D |e verfasserin |4 aut | |
700 | 1 | |a Liu, Z C |e verfasserin |4 aut | |
700 | 1 | |a Jiang, C Q |e verfasserin |4 aut | |
700 | 1 | |a Shi, J |e verfasserin |4 aut | |
700 | 1 | |a Wu, K C |e verfasserin |4 aut | |
700 | 1 | |a Dong, W G |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Zhonghua nei ke za zhi |d 1957 |g 62(2023), 8 vom: 01. Aug., Seite 1000-1006 |w (DE-627)NLM000465526 |x 0578-1426 |7 nnns |
773 | 1 | 8 | |g volume:62 |g year:2023 |g number:8 |g day:01 |g month:08 |g pages:1000-1006 |
856 | 4 | 0 | |u http://dx.doi.org/10.3760/cma.j.cn112138-20220818-00603 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 62 |j 2023 |e 8 |b 01 |c 08 |h 1000-1006 |